Get started
Author

Chikashi Yoshida

A single-cell atlas of non-haematopoietic cells in human lymph nodes and lymphoma reveals a landscape of stromal remodelling
2022 · Yoshiaki Abe, Mamiko Sakata-Yanagimoto, et al. · Nature Cell Biology · 104
PDF
Long range interaction of cis‐DNA elements mediated by architectural transcription factor Bach1
1999 · Chikashi Yoshida, Fuyuki Tokumasu, et al. · Genes to Cells · 98
PDF
Low-dose dasatinib in older patients with chronic myeloid leukaemia in chronic phase (DAVLEC): a single-arm, multicentre, phase 2 trial
2021 · Kazunori Murai, Hiroshi Ureshino, et al. · The Lancet Haematology · 71
PDF
Dasatinib cessation after deep molecular response exceeding 2 years and natural killer cell transition during dasatinib consolidation
2017 · Takashi Kumagai, Chiaki Nakaseko, et al. · Cancer Science · 68
PDF
Bcr-Abl signaling through the PI-3/S6 kinase pathway inhibits nuclear translocation of the transcription factor Bach2, which represses the antiapoptotic factor heme oxygenase-1
2006 · Chikashi Yoshida, Fumiko Yoshida, et al. · Blood · 61
Shorter halving time of BCR‐ABL1 transcripts is a novel predictor for achievement of molecular responses in newly diagnosed chronic‐phase chronic myeloid leukemia treated with dasatinib: Results of the D‐first study of K anto CML study group
2014 · Noriyoshi Iriyama, Shin Fujisawa, et al. · American Journal of Hematology · 49
Biology of Chronic Myeloid Leukemia and Possible Therapeutic Approaches to Imatinib-Resistant Disease
2004 · Chikashi Yoshida, Junia V. Melo · International Journal of Hematology · 46
Regulatory T cell inhibition by dasatinib is associated with natural killer cell differentiation and a favorable molecular response—The final results of the D-first study
2018 · Yuho Najima, Chikashi Yoshida, et al. · Leukemia Research · 41
Feasibility of the imatinib stop study in the Japanese clinical setting: delightedly overcome CML expert stop TKI trial (DOMEST Trial)
2018 · Shin Fujisawa, Yasunori Ueda, et al. · International Journal of Clinical Oncology · 36
PDF
Early cytotoxic lymphocyte expansion contributes to a deep molecular response to dasatinib in patients with newly diagnosed chronic myeloid leukemia in the chronic phase: results of the D‐first study
2015 · Noriyoshi Iriyama, Shin Fujisawa, et al. · American Journal of Hematology · 35
PDF
Discontinuation of Dasatinib after Deep Molecular Response for over 2 Years in Patients with Chronic Myelogenous Leukemia and the Unique Profiles of Lymphocyte Subsets for Successful Discontinuation: A Prospective, Multicenter Japanese Trial (D-STOP Trial)
2016 · Takashi Kumagai, Chiaki Nakaseko, et al. · Blood · 33
Transcriptional suppression of BACH2 by the Bcr-Abl oncoprotein is mediated by PAX5
2012 · D A Casolari, M Makri, et al. · Leukemia · 33
Adherence to the standard dose of imatinib, rather than dose adjustment based on its plasma concentration, is critical to achieve a deep molecular response in patients with chronic myeloid leukemia
2011 · Chikashi Yoshida, Takuya Komeno, et al. · International Journal of Hematology · 31
Association of pyoderma gangrenosum and sterile osteomyelitis in a patient having myelodysplastic syndrome with der(1;7)(q10;q10)
2004 · Chikashi Yoshida, Hiroshi Kojima, et al. · European Journal Of Haematology · 31
Harmonization of molecular monitoring of chronic myeloid leukemia therapy in Japan
2011 · Chikashi Yoshida, Linda Fletcher, et al. · International Journal of Clinical Oncology · 30
Venetoclax plus azacitidine in Japanese patients with untreated acute myeloid leukemia ineligible for intensive chemotherapy
2021 · Kazuhito Yamamoto, Atsushi Shinagawa, et al. · Japanese Journal of Clinical Oncology · 29
Multicenter phase II clinical trial of nilotinib for patients with imatinib-resistant or -intolerant chronic myeloid leukemia from the East Japan CML study group evaluation of molecular response and the efficacy and safety of nilotinib
2014 · Naoto Takahashi, Masatomo Miura, et al. · Biomarker Research · 25
PDF
Relative increase in lymphocytes from as early as 1 month predicts improved response to dasatinib in chronic-phase chronic myelogenous leukemia
2013 · Takashi Kumagai, Eri Matsuki, et al. · International Journal of Hematology · 24
Clinicopathological analyses of 5 Japanese patients with CD56+ primary cutaneous lymphomas.
2000 · H Kojima, H Y Mukai, et al. · PubMed · 22
A new diagnostic kit, ODK-1201, for the quantitation of low major BCR-ABL mRNA level in chronic myeloid leukemia: correlation of quantitation with major BCR-ABL mRNA kits
2015 · Hirohisa Nakamae, Chikashi Yoshida, et al. · International Journal of Hematology · 20
Treatment-free remission after first-line dasatinib treatment in patients with chronic myeloid leukemia in the chronic phase: the D-NewS Study of the Kanto CML Study Group
2020 · Hiroki Yamaguchi, Naoki Takezako, et al. · International Journal of Hematology · 15
Silent NK/T cell reactions to dasatinib during sustained deep molecular response before cessation are associated with longer treatment‐free remission
2020 · Takashi Kumagai, Chiaki Nakaseko, et al. · Cancer Science · 14
PDF
Intravenous itraconazole compared with liposomal amphotericin B as empirical antifungal therapy in patients with neutropaenia and persistent fever
2020 · Isao Yoshida, Akiko M. Saito, et al. · Mycoses · 12
PDF
Association of pleural effusion with an early molecular response in patients with newly diagnosed chronic-phase chronic myeloid leukemia receiving dasatinib: Results of a D-First study
2016 · Maki Hagihara, Noriyoshi Iriyama, et al. · Oncology Reports · 12
PDF
Efficacy of Molecular Response at 1 or 3 Months after the Initiation of Dasatinib Treatment Can Predict an Improved Response to Dasatinib in Imatinib-Resistant or Imatinib-Intolerant Japanese Patients with Chronic Myelogenous Leukemia during the Chronic Phase
2014 · Koiti Inokuchi, Takashi Kumagai, et al. · Journal of the Japan Society of the Reticuloendothelial System · 12
PDF
Works count: 84
Citation count: 1,135
H-index: 20
I10-index: 32
Year
Topic
Type